A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)

In December 2019, a new type viral pneumonia cases occurred in Wuhan, Hubei Province; and then named “2019 novel coronavirus (2019-nCoV)” by the World Health Organization (WHO) on 12 January 2020. For it is a never been experienced respiratory disease before and with infection ability widely and quickly, it attracted the world’s attention but without treatment and control manual. For the request from frontline clinicians and public health professionals of 2019-nCoV infected pneumonia management, an evidence-based guideline urgently needs to be developed. Therefore, we drafted this guideline according to the rapid advice guidelines methodology and general rules of WHO guideline development; we also added the first-hand management data of Zhongnan Hospital of Wuhan University. This guideline includes the guideline methodology, epidemiological characteristics, disease screening and population prevention, diagnosis, treatment and control (including traditional Chinese Medicine), nosocomial infection prevention and control, and disease nursing of the 2019-nCoV. Moreover, we also provide a whole process of a successful treatment case of the severe 2019-nCoV infected pneumonia and experience and lessons of hospital rescue for 2019-nCoV infections. This rapid advice guideline is suitable for the first frontline doctors and nurses, managers of hospitals and healthcare sections, community residents, public health persons, relevant researchers, and all person who are interested in the 2019-nCoV.

[1]  Fu-chun Zhang,et al.  [Clinical analysis of 190 cases of outbreak with atypical pneumonia in Guangzhou in spring, 2003]. , 2003, Zhonghua yi xue za zhi.

[2]  P. Dong,et al.  [Use of glucocorticoid in treatment of severe acute respiratory syndrome cases]. , 2003, Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine].

[3]  V. Wong,et al.  Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. , 2003, Hong Kong medical journal = Xianggang yi xue za zhi.

[4]  Y. Guan,et al.  Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings , 2004, Thorax.

[5]  Guang-wei Li,et al.  [Glucocorticoid-induced diabetes in severe acute respiratory syndrome: the impact of high dosage and duration of methylprednisolone therapy]. , 2004, Zhonghua nei ke za zhi.

[6]  Lai St.  Treatment of severe acute respiratory syndrome , 2005 .

[7]  S. Lai,et al.  Treatment of severe acute respiratory syndrome , 2005, European Journal of Clinical Microbiology and Infectious Diseases.

[8]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[9]  Arthur S Slutsky,et al.  Acute Respiratory Distress Syndrome The Berlin Definition , 2012 .

[10]  M. Katze,et al.  Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques , 2013, Nature Medicine.

[11]  Z. Memish,et al.  Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study , 2014, The Lancet Infectious Diseases.

[12]  C. Wenisch,et al.  1225: MERS-COV DISEASE ASSOCIATED ARDS −A CASE REPORT , 2015 .

[13]  Tae Hyong Kim,et al.  Middle East Respiratory Syndrome Infection Control and Prevention Guideline for Healthcare Facilities , 2015, Infection & chemotherapy.

[14]  Jian-Piao Cai,et al.  Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset , 2015, The Journal of infectious diseases.

[15]  H. Schünemann,et al.  [GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction.] , 2017, Recenti progressi in medicina.

[16]  G. Gartlehner,et al.  [GRADE: Evidence to Decision (EtD) frameworks - a systematic and transparent approach to making well informed healthcare choices. 1: Introduction]. , 2018, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.

[17]  F. Dentali,et al.  McMaster RARE‐Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome , 2018, Journal of thrombosis and haemostasis : JTH.

[18]  G. Guyatt,et al.  [GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines]. , 2018, Gaceta sanitaria.

[19]  A. Oxman,et al.  Distinguishing opinion from evidence in guidelines , 2019, BMJ.

[20]  S. Lo,et al.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster , 2020, The Lancet.

[21]  S. Perlman,et al.  Another Decade, Another Coronavirus , 2020, The New England journal of medicine.

[22]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[23]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[24]  WHO ADVICE FOR INTERNATIONAL TRAVEL AND TRADE IN RELATION TO THE OUTBREAK OF PNEUMONIA CAUSED BY A NEW CORONAVIRUS IN CHINA , 2020, Saudi Medical Journal.

[25]  Hongfei Deng,et al.  The possibility of using Lopinave/Litonawe (LPV/r) as treatment for novel coronavirus 2019-nCov pneumonia: a quick systematic review based on earlier coronavirus clinical studies/ 中华急诊医学杂志 , 2020 .

[26]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.